FIELD: chemistry.
SUBSTANCE: invention relates to amatoxins of general formula (An), where n is 2, 3, 4, 5, 6, 7, 8 or 9. Invention also relates to an antibody-drug conjugate (ADC) consisting of an antibody conjugated to amatoxin through a linker, wherein the ADC has structural formula (Ia), where Q is S; L is -(CH2)n, wherein n is integer from 1 to 6; Z is a maleimide group; and Ab is an antibody which specifically binds to Her2 or PSMA. Invention also relates to an antibody-drug conjugate (ADC), wherein the antibody specifically binds to human PSMA and contains heavy and light chain amino acid sequences and which is conjugated with HDP30.2867 compound. Invention also relates to the use of ADC for treating cancer. (HDP30.2867).
EFFECT: providing amatoxins which can be used in antibody-drug conjugates (ADC) for delivering amatoxin to a target cell, which have high plasma stability and tolerance in vivo.
16 cl, 15 tbl, 48 dwg, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| ANTI-CEACAM6 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2739163C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
